Dr. Christos Fountzilas

Christos Fountzilas

MD, FACP
Medical Oncology

Specializing In:

Pancreatic Cancer Liver Cancer Colon Cancer Esophageal Cancer

Special Interests:

Personalized therapy of gastrointestinal malignancies Immunotherapy for gastrointestinal malignancies Oncolyitic viruses Drug development Biomarker identification

About Christos Fountzilas

Biography:

Dr. Fountzilas is a board certified medical oncologist in the gastrointestinal medical oncology department at Roswell Park Comprehensive Cancer Center with a focus in pancreatic cancer. His research interests include oncolytic virotherapy, biomarker discovery, and immunotherapy for gastrointestinal cancers. His interest was sparked in gastrointestinal and clinical research during his fellowship training at the University of Texas Health Science Center at San Antonio where he designed a clinical trial involving combination immunotherapy and oncolytic viral therapy in relapsed adenocarcinoma of the pancreas. He gained further experience in clinical trial design through his participation in the American Association for Cancer Research/American Society of Clinical Oncology 2015 Methods in Clinical Cancer Research Workshop and Cancer Research Training Program from Cancer Prevention and Research Institute of Texas.

Positions

Roswell Park Comprehensive Cancer Center

  • Assistant Professor of Oncology

Background

Education and Training:

  • 2000-2006 - MD - Aristotle University of Thessaloniki School of Medicine

Residency:

  • 2007-2008 - Post Graduate Internship, Athens Naval Hospital and Veterans Medical Center, Hellenic Navy, Athens, Greece
  • 2010-2013 - Internal Medicine, Lenox Hill Hospital, Hofstra Northwell School of Medicine, New York, New York

Fellowship:

  • 2013-2016 - Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas

Board Certification:

  • Medical Oncology Board Certification, Greece
  • American Board of Internal Medicine-Certification in Medical Oncology
  • American Board of Internal Medicine-Certification in Hematology
  • American Board of Internal Medicine-Certification in Internal Medicine

Professional Memberships:

  • American Association for Cancer Research
  • European Society for Medical Oncology
  • American Society of Clinical Oncology
  • American College of Physicians
  • North American Neuroendocrine Tumor Society
  • American College of Gastroenterology
  • Athens Medical Association

Professional Experience:

  • 2013-2016 - Hematology/Medical Oncology Fellowship, University of Texas Health Science Center at San Antonio, San Antonio, TX
  • 2010-2013 - Internal Medicine Residency, Lenox Hill Hospital, New York, NY
  • 2007-2010 - Medical Officer, Hellenic Navy, Athens, Greece

Honors & Awards:

  • 2020 - Pancreatic Cancer Action Network (PANCAN) Patient Champions
  • 2019 - Fellow, American College of Physicians
  • 2015-2016 - Cancer Research Training Program from Cancer Prevention and Research Institute of Texas, RP140105
  • 2015 - Harold F. and Sarah L. McDonald Scholar Award for Excellence in Oncology
  • 2015 - AACR/ASCO 2015 Methods in Clinical Cancer Research Workshop
  • 2009 - Hellenic Republic Medal for participation in international peacekeeping operations
  • 2008 - United Nations Peacekeeping Medal
  • 2006-2007 - Hellenic State Scholarship Foundation Award
  • 2005-2006 - Hellenic State Scholarship Foundation Scholarship

Clinical Trials


Featured on Cancer Talk


Publications

Full Publications list on PubMed
  • Iyer R, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang K, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy D, Shah M. Multicenter Phase II Trial of Nintedanib in Advanced Non-Pancreatic Neuroendocrine Tumors. Cancer 2020 Jun 11. doi: 10.1002/cncr.32994.

  • Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estfan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer RV. A Multicenter Phase Ib/II Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma. Br J Cancer 122, 963–970 (2020). doi: 10.1038/s41416-020-0737-6

  • Mahalingam D, Wilkinson G, Eng K, Fields P, Raber P, Moseley J, Cheetham K, Coffey M, Nuovo G, Kalinski P, Zhang B, Arora S, Fountzilas C. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma, a Phase 1b study. Clin Cancer Res. 2019 Nov 6. pii: clincanres.2078.2019. doi: 10.1158/1078-0432.CCR-19-2078.

  • Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1 open label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 Oct 9. doi: 10.1002/cncr.31676.

  • Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Jul 12. doi: 10.1007/s00280-017-3375-9